{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:26:46Z","timestamp":1768444006649,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1124\/dmd.120.090951","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T05:25:19Z","timestamp":1591421119000},"page":"690-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture"],"prefix":"10.1016","volume":"48","author":[{"given":"Tom S.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Sun","family":"Scaringella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klairynne","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.090951_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2125.1994.tb04336.x","article-title":"Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms","volume":"38","author":"Andersson","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090951_bib2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1208\/s12248-016-9962-6","article-title":"Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance","volume":"18","author":"Argikar","year":"2016","journal-title":"AAPS J"},{"key":"10.1124\/dmd.120.090951_bib3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2125.1989.tb05410.x","article-title":"Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro","volume":"28","author":"Back","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090951_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yexcr.2017.12.023","article-title":"Liver \u2018organ on a chip\u2019","volume":"363","author":"Beckwitt","year":"2018","journal-title":"Exp Cell Res"},{"key":"10.1124\/dmd.120.090951_bib5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/dmd.115.069096","article-title":"Evaluation of a new molecular entity as a victim of metabolic drug-drug interactions-an industry perspective","volume":"44","author":"Bohnert","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib6","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","article-title":"Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015","volume":"44","author":"Cerny","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.dmpk.2018.01.004","article-title":"Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: a siRNA-silencing-based approach","volume":"33","author":"Chan","year":"2018","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.120.090951_bib8","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1124\/dmd.113.053397","article-title":"Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac [published correction appears in Drug Metab Dispos (2014) 42:200; Drug Metab Dispos (2019) 47:58\u201366]","volume":"41","author":"Chan","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1124\/dmd.111.040634","article-title":"Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions","volume":"39","author":"Chen","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/17460441.2017.1367280","article-title":"Reaction phenotyping to assess victim drug-drug interaction risks","volume":"12","author":"Di","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/dmd.120.090951_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00003088-200746120-00004","article-title":"Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies","volume":"46","author":"Eberl","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.120.090951_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1124\/dmd.105.008607","article-title":"Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion","volume":"34","author":"Eriksson","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1124\/dmd.31.7.861","article-title":"Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein","volume":"31","author":"Evans","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1081\/DMR-120023684","article-title":"New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures","volume":"35","author":"Gebhardt","year":"2003","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.120.090951_bib15","first-page":"275","article-title":"Alternatives to the use of fetal bovine serum: serum-free cell culture","volume":"20","author":"Gstraunthaler","year":"2003","journal-title":"ALTEX"},{"key":"10.1124\/dmd.120.090951_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.120.090951_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0079-6468(08)00206-3","article-title":"Cytochrome P450 metabolism and inhibition: analysis for drug discovery","volume":"47","author":"Jones","year":"2009","journal-title":"Prog Med Chem"},{"key":"10.1124\/dmd.120.090951_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nbt1361","article-title":"Microscale culture of human liver cells for drug development","volume":"26","author":"Khetani","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1124\/dmd.120.090951_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-011-0024-2","article-title":"Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity","volume":"36","author":"Khojasteh","year":"2011","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.120.090951_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2125.1997.t01-1-00626.x","article-title":"Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine","volume":"44","author":"Kirkwood","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090951_bib21","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0090-9556(24)13663-X","article-title":"Effects of macrolide antibiotics on CYP3A expression in human and rat hepatocytes: interspecies differences in response to troleandomycin","volume":"28","author":"Ledirac","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib22","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/dmd.115.066027","article-title":"Prediction of drug clearance and drug-drug interactions in microscale cultures of human hepatocytes","volume":"44","author":"Lin","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1124\/dmd.120.090951_bib24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1124\/dmd.117.079236","article-title":"Sandwich-cultured hepatocytes for mechanistic understanding of hepatic disposition of parent drugs and metabolites by transporter-enzyme interplay","volume":"46","author":"Matsunaga","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0090-9556(24)15182-3","article-title":"An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation","volume":"28","author":"Mayhew","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0091270003260336","article-title":"Human liver aldehyde oxidase: inhibition by 239 drugs","volume":"44","author":"Obach","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/dmd.120.090951_bib28","first-page":"1","article-title":"Binding of erythromycin base to human plasma proteins","volume":"8","author":"Prandota","year":"1980","journal-title":"J Int Med Res"},{"key":"10.1124\/dmd.120.090951_bib29","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1124\/dmd.115.065326","article-title":"Determination of a degradation constant for CYP3A4 by direct suppression of mRNA in a novel human hepatocyte model, HepatoPac","volume":"43","author":"Ramsden","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3109\/00498254.2010.500407","article-title":"Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds","volume":"40","author":"Sohlenius-Sternbeck","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.090951_bib31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/dmd.106.009738","article-title":"Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode","volume":"34","author":"Takeda","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1994.tb04317.x","article-title":"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine","volume":"38","author":"von Moltke","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.120.090951_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-62703-435-7_16","article-title":"In vitro identification of cytochrome P450 enzymes responsible for drug metabolism","volume":"1015","author":"Yan","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.120.090951_bib34","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.115.067876","article-title":"Novel cytochrome P450 reaction phenotyping for low-clearance compounds using the hepatocyte relay method","volume":"44","author":"Yang","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/17425255.3.5.667","article-title":"Cytochrome P450 reaction-phenotyping: an industrial perspective","volume":"3","author":"Zhang","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.120.090951_bib36","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0090-9556(24)13673-2","article-title":"Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid","volume":"28","author":"Zhou","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090951_bib37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/dmd.114.058750","article-title":"Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes","volume":"43","author":"Zientek","year":"2015","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.090951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:59:48Z","timestamp":1739905188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0090955624079674"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.090951","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.090951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}